HK eBus Corp. (fka HKEB)

[hedge_fun]

Is VPRS going to the NASDAQ?.....LINKS!

Asking such a question about an OTC stock generally brings a chuckle and is normally dismissed in quick order. Running the risk of rambling, here's a review of recent events intended to remove the chuckle in exchange for some serious thought.

In an 8K filed May 5th, VPRS announced the appointment of 4 new officers as well as the selling of 35 million shares by the former CEO. It was not known until yesterday that the price that those 35 million shares went for .10 per share when the former CEO filed a form 4A.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8070981

The 4 new officers announced in the May filing included the new CEO, Dr. Dainwen Ju. Dr. Ju is also the CEO and Chairman of MediPharm Biotech Pharmaceuticals Co. Ltd. that has a drug called Vivatuxin® undergoing a “post market” clinical trial sponsored by China’s Ministry of Health targeting tumors in the lungs.

http://www.chictr.org/(S(4ygrzgqou1wtb355dxhh45ns))/Site/TaskView.aspx?ID=4aacb1d2-e24b-47eb-8dce-9e8941c22362

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7908372

Vivatuxin® is expected to generate over $250,000,000 in revenues through 2013 according to information provided last year by the company at an investors conference.

MediPharm plans to invest in Radiation-Protective Facilities (RPFs) in 150 China Tier 3 hospitals, with each hospital requiring investment of $75,000 for a total of $11.3 million. Vivatuxin® is expected to generate $45.1 million revenue and $13.8 million net profit in 2011, $92.8 million revenue and $36.1 million net profit in 2012, and $143.3 million revenue and $52.1 million net profit in 2013.

http://www.wallstreetresearch.org/reports/profile_medipharm.pdf

VPRS also filed a 13D yesterday revealing the 35 million shares sold in April, were being held in escrow by a New York law firm that specializes in reverse mergers and has access to capital.

Clients of our firm benefit as well from the enhanced access to capital markets available through our financial services affiliates, Gottbetter Capital Markets, LLC (a FINRA-registered broker-dealer), and Gottbetter Capital Group, Inc.

http://www.gottbetter.com/

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8070975

Now those links above do not mean an uplisting is coming, but it does raise some serious questions in my opinion........

*Why would the CEO and Chairman of a biotech company that sought financing a year ago at a small cap investor conference be named as the new CEO and Chairman of a clean shell bought for .10 per share?

*Why use a law firm that has an affiliate that is FINRA registered?

*Why is a former employee of Dr. Ju's biotech company now a new officer with VPRS, and is also the vice general manager of investments in China for Hybrid Kinetic Group? (HKG is traded on the Hong Kong exchange and has a market cap close to $1B).

*Why are the 2 other officers with VPRS also officers with a company held by a Hybrid Kinetic Group subsiiary?

*Why announce a new auditor last month?

*Wouldn't curent sales from Vivatuxin® meet the NASDAQ minimum requirements for listing on that exchange?

Since announcing new management in early May, VPRS has yet to provide any details as to what these SEC filings mean. When I spoke with VPRS's secretary Vincent Wang yesterday, he revealed nothing new, but did say they were "close" to announcing what this all means.

disclaimer: I own shares of VPRS